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Abstract Non-invasive mechanical ventilation (NIV) was originally used in patients with acute
respiratory compromises or exacerbations of chronic respiratory diseases as an alternative to
intubation. Over the last thirty years NIV has been used during the night in patients with sta-
ble chronic lung diseases such as obstructive sleep apnea, the overlap syndrome (COPD and
obstructive sleep apnea), neuromuscular disorders, obesity-hypoventilation syndrome and in
other conditions such as sleep disorders associated with congestive heart failure.
In this review we discuss the different types of NIV, the speciﬁc conditions in which they can
be used as well as the indications, recommendations, and evidence supporting the efﬁcacy of
NIV.
© 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights
reserved.
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Distúrbios
Ventilac¸ão não invasiva no tratamento de distúrbios respiratórios do sono: análise e
actualizac¸ãorespiratórios do sono;
Ventilac¸ão não
invasiva;
Pressão positiva
contínua das vias
Resumo A ventilac¸ão mecânica não invasiva (VNI) foi originalmente usada em doentes com
insuﬁciência respiratória aguda ou em exacerbac¸ões de doenc¸a respiratória crónica, como
uma alternativa à intubac¸ão. Nos últimos trinta anos, a VNI tem sido usada durante a noite,
em doentes com doenc¸as pulmonares crónicas estáveis, como a apneia obstrutiva do sono, a
síndrome de sobreposic¸ão (DPOC - doenc¸a pulmonar obstrutiva crónica - e apneia obstrutiva
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aéreas;
Pressão positiva em
dois níveis nas vias
aéreas
do sono), disfunc¸ões neuromusculares, síndrome de hipoventilac¸ão e obesidade, e em outras
doenc¸as como os distúrbios do sono associados a insuﬁciência cardíaca congestiva.
Nesta análise discutimos os diferentes tipos de VNI, as condic¸ões especíﬁcas em que cada um
deles pode ser usado, assim como as indicac¸ões, recomendac¸ões e a evidência que comprova a
eﬁcácia da VNI.
© 2013 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L.U. Todos os
direitos reservados.
Table 1 Main diseases which can beneﬁt from NIV classiﬁed
according the cause and progressiveness of the respiratory
impairment.1,2
Parietal disorders
Chest wall
Kyphoscoliosis No worsening
Sequelae of tuberculosis Slow worsening
Obesity hypoventilation
syndrome (OHS)
Depends on obesity
Neuromuscular
Spinal muscular atrophy No worsening
Acid maltase deﬁcit Slow worsening (>15 y)
Duchene dystrophy Intermediate worsening
(5--15 y)
Myotonic myopathy Intermediate worsening
Amyotrophic lateral
sclerosis
Rapid worsening (0--3 y)
Lung diseases
Chronic obstructive
pulmonary disease
Continuous worsening
Bronchiectasis and Cystic
ﬁbrosis
Continuous worsening
Predominant ventilatory control abnormalities
Ondine’s curse No worsening
Cheyne-Stokes breathing Depends on heart failure
Upper airway abnormalities
Pierre Robin syndrome No worsening
u
i
pharynx.2 The upper airway becomes less efﬁcient, reducing
oropharyngeal space especially at the end of exhalation. As
a result, at the beginning of the next inspiration the dilator
Table 2 Typical symptoms of OSA.1,2
Snoring
Nocturia
Unrefreshing sleep
Choking
Daytime sleepiness
Decreased libidoBackground
Noninvasive mechanical ventilation (NIV) is any form of
ventilatory support without an endotracheal tube. NIV was
originally used in patients with acute respiratory compro-
mises or exacerbations of chronic respiratory diseases, as
an alternative to the endotracheal tube. Over the last thirty
years NIV has been also used during the night in patients
with stable chronic lung disease such as obstructive sleep
apnea (OSA), chronic obstructive pulmonary disease (COPD),
the overlap syndrome (COPD and obstructive sleep apnea),
neuromuscular disorders, obesity-hypoventilation syndrome
(OHS), and sleep disorders associated with congestive heart
failure (Cheyne-Stokes respiration).1,2 In this review we dis-
cuss the different types of NIV, the speciﬁc conditions in
which they can be used as well as the indications, recom-
mendations and evidence supporting the efﬁcacy of NIV.
Clinical conditions for NIV
Alveolar hypoventilation is a result of an imbalance between
the capability of respiratory muscles to maintain ventila-
tion and gas exchange and is characterized by hypercapnia
assessed by blood gas analysis. If pathologies related to
either peripheral and/or central nervous system dysfunction
are excluded, the other conditions associated with develop-
ing alveolar hypoventilation are listed in Table 1.1--3 Of note,
alveolar hypoventilation primarily develops during sleep4;
moreover, in all these entities daytime breathing abnor-
malities must be considered. These respiratory ‘‘daylight’’
deteriorations (particularly in patients with neuromuscular
disorders) require an appreciation of the diagnosis, the pro-
gression of the disease, and the particular circumstances of
the patient.1--3
Obstructive sleep apnea--hypoapnea syndrome
(OSA)
OSA has an incidence of 2% in women and 4% in men.5,6 It
is characterized by recurrent episodes of partial (hypoap-
nea) or complete (apnea), obstruction of the upper airway
during sleep, and is associated with episodes of arousal
and/or oxyhemoglobin desaturation.7,8 Symptoms of the
syndrome include excessive daytime sleepiness, choking
episodes during sleep, frequent awakenings, unrefreshing
and unstructured sleep, daytime fatigue, difﬁculty con-
centrating and short-term memory loss1 (Table 2). The
pathophysiology of OSA remains controversial. Obesity, the
classic hallmark in OSA, is associated with obstruction of theObstructive sleep apnea No worsening
pper airways.9 Possible hypotheses include adipose tissue
nfarction of the tongue and/or the dilator muscles of theMorning headache
Enuresis
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uscles of the pharynx must produce a greater contraction
o overcome the tendency of the pharyngeal wall to col-
apse (due to the negative pressure inside the cavity and
harynx).7 The supine position is potentially dangerous in
ome circumstances8,9 because the tongue tends to occlude
he rear wall of the oropharynx which can increase the
ropharynx occlusion.9,10 This syndrome has been associated
ith the development of hypertension,11 coronary artery
isease, bleeding disorders, stroke and increased risk of sud-
en death during sleep.12--14 It is also associated with a higher
ate and greater severity of trafﬁc accidents, increased use
f health care facilities and reduced capacity for work.12,14,15
trong evidence exists that non-invasive ventilation, usually
ontinuous airway positive pressure (CPAP), has signiﬁcant
dvantages in this type of disease, improving sleep qual-
ty, daytime wakefulness, and cognitive function15 and so
he quality of life improves. These improvements are wide-
anging: reduction of trafﬁc accidents, lower arterial blood
ressure and reduction in the morbidity and mortality rates
f myocardial infarction and stroke demonstrate the wide
pectrum of CPAP’s beneﬁts.3,12,15,16
omplex sleep apnea
e use the term ‘‘Complex Sleep Apnea’’ (CompSAS) to
ndicate a condition initially diagnosed as OSA. This syn-
rome is characterized (while CPAP is being used) by the
requent occurrence of central apneoa after elimination of
bstructive events.17,18 CompSAS is diagnosed based on min-
mal apnea--hypoapnea index (AHI) of ﬁve events per hour
f sleep with a majority of obstructive events. If during
itration there is a reduction in the number of obstructive
vents to <5 events per hour of sleep, while the central
pnea index (CAI) is >5 events per hour sleep, the diagnosis
s established.18,19 Rather than starting further treatments
t is useful to consider whether CPAP pressure is too high and
s provoking CompSAS (pressure toxicity).20 Patients with
ompSAS most often respond to positive airway pressure,
ut the obstruction cannot be eliminated without produc-
ng central apnea. A possible preventive measure is the
o-called permissive ﬂow-limitation: the pressure is set at a
evel that permits a mild degree of airway obstruction, with-
ut disturbing ventilator control mechanisms.17 Also oxygen
dministration may lead to a decrease in the hypoxic venti-
atory response.17,21,22 Also BiPAP in the spontaneous-timed
ST) mode17,23 or adaptive servo-ventilation (ASV) can be
seful in the treatment of CompSAS.17,18,24
leep-disturbances associated with cardiac
ysfunction
he prevalence of obstructive sleep apnea in patients with
mpaired left ventricular ejection fraction is estimated to be
bout 11--53%.25 It is also known that the sleep obstructive
pnea--hypoapnea syndrome can worsen a state of conges-
ive heart failure, by causing a periodic increase in negative
ntrathoracic pressure, by raising arterial blood pressure,
nd causing tachycardia from sympathetic nervous system
timulation from hypoxia, hypercapnia and arousals.26
CPAP treatment produces a reduction in blood pressure
nd improves left ventricular systolic function in patients
a
t
m
rA. Nicolini et al.
ith chronic heart failure and obstructive sleep apnea.11,25
ecent studies in patients with chronic heart failure asso-
iated with obstructive sleep apnea have shown a further
mprovement in cardiac function in patients treated with
ilevel positive airway pressure ventilation (BIPAP).27 This
ay be due to the lower respiratory muscle work due to
IPAP. Moreover, reduced work of breathing, a lower positive
ntrathoracic pressure gives a greater ejection fraction.28
entral sleep apnea (CSA) is associated with periodic breath-
ng. Periodic breathing, Cheyne-Stokes respiration, is a
articular variety of central sleep apnea which is fre-
uently associated with congestive heart failure.29 CSA with
ts characteristic desaturation (apnea-related) and sympa-
hetic hyperactivity tends to worsen the prognosis of heart
ailure. CSA is characterized by cessation of respiratory drive
uring sleep, which causes impaired gas exchange.27 Unlike
he OSA in which there is a respiratory effort to overcome
he resistance of the upper airway, CSA is characterized
y the absence of respiratory movement due to the ces-
ation of ventilation. In the heart failure patients, the onset
f apnea occurs through a redistribution of blood volume
rom the lower limbs to pulmonary circulation that is pri-
arily triggered by the supine position.27,29 Stimulation of
ulmonary vagal receptors causes hyperventilation which
esults in hypocapnia. When the value decreases below the
ypocapnic apnoeic threshold, stimulation of the bulbar
enter ceases, inspiratory drive stops, and apnea occurs.
n patients with chronic heart failure, the prolonged cir-
ulation time due to the reduction in cardiac output leads
o a delay of feedback between chemoreceptors and bul-
ar centers resulting in hyperventilation and respiratory
nstability.30 The main risk factors for CSA are male sex,
ypocapnia, atrial ﬁbrillation and advanced age. CPAP and
IPAP are often unable to correct this category of apneas;
herefore, a servo-assisted mode (ASV or adaptive servo ven-
ilation) is recommended.29,31
The ASV device determinate automatically the extent
f ventilatory support based on a continuous analysis of
he breathing pattern and in more advanced machines also
he expiratory pressure adjustment.18,24 Some studies have
hown it to be most effective in controlling this type of
pnea;32 it remains unclear whether ASV increases survival
n these patients.33,34
besity-hypoventilation syndrome
besity hypoventilation refers to a syndrome including day-
ime hypercapnia (PCO2 > 45mmHg) in obese people in which
o other cause of hypoventilation is present.35 Its preva-
ence among patients with obstructive sleep apnea is 20--30%
nd is greater in extremely obese patients (BMI > 40).36,37
pproximately 10% of patients with obesity-hypoventilation
yndrome do not have obstructive sleep apnea syndrome.
dditionally, nocturnal hypoxemia and diurnal hypercapnia
ersist in about 40% of these patients after the treatment
hen CPAP eliminated apnea.35,36 Other factors contribute
o the development of obesity-hypoventilation syndrome
ssociated with the persistence of daytime hypercapnia:
hese include body mass index and apnea--hypoapnea index,
ean overnight oxygen saturation, and the severity of
estrictive ventilatory syndrome.37 CPAP treatment is most
327
Table 3 Clinical features frequently associated with alve-
olar hypoventilation.1,2
Shortness of breath during activities of daily in the absence
of paralysis
Orthopnea in patients with disordered diaphragmatic
dysfunction
Poor sleep quality: insomnia, nightmares and frequent
arousals
Nocturnal or early morning headaches
Daytime fatigue, drowsiness, loss of energy
Decrease in intellectual performance
Appearance of recurrent complications: respiratory
infections
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effective when there are certain predictive values: better
spirometry results, and a higher apnea--hypoapnea index.
BIPAP therapy may be useful in those patients for whom
CPAP has failed or given unsatisfactory results. Titration of
non-invasive ventilation pressure should follow the recom-
mendations of pressure titration in obstructive sleep apnea
with the goal of eliminating (hypo)apneas, snoring, respira-
tory effort-related arousals and lowering pCO2 levels to at
least daytime values.38 No recommendations exist regarding
the ventilation mode to favor in OHS.39 Trials exist provid-
ing evidence that a high backup respiratory rate leads to
superior night-time control of respiratory events.40,41
The average volume-assured pressure support ventilation
seems to be able to lower pCO2, but data regarding effect
on oxygenation and long-term outcome are conﬂicting.42--45
Neuromuscular and chest wall disorders
NIV has been used in patients with progressive neuromus-
cular disease or serious abnormalities of the thoracic cage,
with recognized beneﬁts, which include an improved sur-
vival rate and an improved quality of life. The beneﬁts of
NIV in this type of patient includes improvements of daytime
levels of blood gas (including hypercapnia), a reduction in
the oxygen cost of breathing, an increase in the ventilatory
response to increased carbon dioxide, and improved lung
compliance.46
Chronic obstructive pulmonary disease and sleep
apnea (overlap syndrome)
COPD is a challenging and ever increasing chronic pulmonary
disease, affecting health care systems worldwide. It is pro-
jected to be fourth leading cause of mortality by 2030.
COPD severely impacts quality of life.47 In severe COPD
acute exacerbations often lead to acute hypoxemic and/or
hypercapnic respiratory failure, resulting in further disease
progression and possible chronic respiratory failure.48
NIV is considered ﬁrst-line treatment in acute exa-
cerbations of COPD requiring ventilatory support,49 but
recommendations regarding establishment of domiciliary
long-term non-invasive ventilation in chronic hypercapnic
failure due to COPD are conﬂicting.50 Sleep-disordered
breathing (mainly obstructive sleep apnea) and chronic
obstructive pulmonary disease (COPD) are the most
common lung diseases: a large number of patients
have both disorders, hence the term ‘‘overlap syn-
drome.’’51,52
The COPD overlap syndrome was ﬁrst described by
Flenley in 1985 as a combination of COPD and obstruc-
tive apnea--hypoapnea syndrome.53 Epidemiological studies
have not shown a consistently higher incidence of sleep
apnea--hypoapnea syndrome in patients with COPD com-
pared to common OSA.52 Nevertheless, the coexistence of
these conditions can lead to severe episodes of desatura-
tion during sleep (particularly during rapid eye moviment --
REM-sleep),54 thus increasing the risk of hypoxemia, daytime
hypercapnia and pulmonary hypertension.55 This results in
a substantially greater morbidity and mortality, compared
to those with COPD or OSA alone as well as more hospital-
izations and higher mortality. Many questions remain about
f
w
w
bClinical signs of cor pulmonale
he deﬁnition of the disease, the prognosis and the optimal
reatment which currently consists of CPAP and oxygen. Non-
nvasive ventilation may be useful in patients with overlap
yndrome, but there are no controlled studies.56,57
linical criteria for starting non-invasive
entilation
he presence of symptoms and physiological markers
f hypoventilation are useful in identifying the clinical
everity; moreover, these factors relate to therapeu-
ic decision-making, especially initiating nocturnal non-
nvasive ventilation.1,2 In a typical ‘‘progressive disease’’
wo consecutive steps occur:
1) Initial phase of nocturnal hypoventilation reversible dur-
ing waking hours, associated with few or no clinical
symptoms.
2) Nocturnal and daylight hypoventilation associated with
clinical symptoms (see Table 3) which shows a reduced
respiratory reserve.
Continuous sleep monitoring of pCO2 and O2 saturation
alues is necessary to document the presence of noc-
urnal hypoventilation which may be present in all the
tages of sleep (in some cases only during REM sleep).
aytime hypoventilation is deﬁned by reduced values of
rterial oxygen tension (PaO2 <55mmHg), high levels of
rterial carbon dioxide tension (PaCO2 46--50mmHg) and/or
igh serum bicarbonate levels with a relatively normal pH.
hronic daytime hypoventilation is an important indicator
lways associated with nocturnal hypoventilation (PaCO2
55mmHg or a rise in PtcCO2 to ≥10mmHg).52 In the
resence of daytime hypoventilation, polysomnography is
ecommended to exclude sleep apnea.2 Clinical symptoms,
lthough modest, should be evaluated carefully, because
hey are very important determining disease severity and
rognosis as well deﬁning the need for NIV. Pulmonary func-
ion tests may be helpful in deﬁning the reduction of lung
unction, but they have a low predictive value for patients
ith sleep-related hypoventilation.2,52 However, in patients
ith neuromuscular disease, there is a good correlation
etween lung function and nocturnal hypoventilation: it has
3b
a
s
1
T
W
s
c
C
C
t
a
f
o
i
c
a
a
l
(
(
A
p
A
d
d
r
t
b
h
T
c
v
o
h
t
t
d
i
t
A
T
f
a
w
c
c
p
t
i
p
s
a
t
c
B
B
s
l
B
t
l
t
(
q
a
r
f
t
r
p
o
e
i
t
s
o
s
o
b
s
h
b
p
s
A
p
A
v
A
(
i28
een shown that hypoventilation during REM only or during
ll sleep stages or in the daytime, appears respectively with
upine inspiratory vital capacities of less than 40%, 25% or
2% of predicted values.1,58
ypes of NIV and their use
e now consider the main types of ventilation used to treat
leep-disordered breathing and respiratory conditions asso-
iated with hypoventilation and hypercapnia.
PAP (continuous positive airway pressure)
PAP is currently the most widely used mode of NIV in
he treatment of obstructive sleep-disordered breathing59
nd acute hypoxemic failure associated with chronic heart
ailure.59,60 It consists in the application of a constant level
f positive pressure during spontaneous breathing. However,
t has to be noted that CPAP should be only applied in sufﬁ-
iently spontaneous breathing patients. It is not considered
s a mode of mechanical ventilation.61 The mechanism of
ction of CPAP includes a series of actions on pathophysio-
ogical mechanisms:
(a) It prevents intermittent narrowing and collapse
of the airways in patients with obstructive sleep
apnea--hypoapnea syndrome (by acting a virtual splint
during sleep).
b) It counteracts auto-positive end-expiratory pressure,
which reduces respiratory muscles load, the work of
breathing and daytime PaCO2 in patients with overlap
syndrome.
(c) It improves lung function, particularly the functional
residual capacity, daytime gas exchange in patients with
obstructive sleep apnea--hypoapnea syndrome.
d) It improves systolic function of the left ventricle in
patients with heart failure coexisting with obstructive
sleep apnea--hypoapnea syndrome.3
uto-CPAP (automatic adjustment of continuous
ositive airway pressure)
uto-CPAP (APAP) is delivered via a self-titrating CPAP
evice, which uses algorithms to detect variations in the
egree of obstruction and adjusts the pressure level to
estore normal breathing. Auto-CPAP compensates for fac-
ors that modify the upper airway collapsibility, such as
ody position during sleep, stage of sleep, use of alco-
ol, and drugs that affect upper airway muscle tone.2,3
he auto-CPAP can be used during polysomnography or
ardiorespiratory monitoring to titrate a single pressure
alue to be used later with ﬁxed CPAP for treatment
f OSA in patients without comorbid conditions (chronic
eart failure, COPD, central apnea syndrome or hypoven-
ilation). The use of auto-CPAP is reserved only for
hose patients with sleep apnea syndrome only present
uring REM or respiratory events related to position,
n whom constraining positional maneuvers are poorly
olerated.62
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daptive servo-ventilation (ASV)
he adaptive servo-ventilation (ASV) has been developed
or the treatment of Cheyne-Stokes respiration-central
pnea syndrome in patients with chronic heart failure
ho have a breathing pattern characterized by periods of
rescendo--decrescendo change in tidal volume. This more
omplex device can use patient expiratory positive airway
ressure (EPAP) level sufﬁcient to control the obstruc-
ive apnea. The device then automatically adjusts the
nspiratory pressure support for each inspiration within a
re-speciﬁed range, to maintain a moving-target ventilation
et at 90% of the patient’s recent average ventilation. The
im is the stabilization of breathing patterns and to reduce
he respiratory alkalosis which can trigger apnea re-entry
ycles.29,30,63,64
IPAP (bilevel positive airway pressure)
ilevel positive airway pressure (BIPAP) is also used for
leep-related disorders, but its main indication is in patho-
ogical conditions associated with hypoventilation. The
IPAP devices deliver a higher pressure during inspira-
ion (IPAP -- inspiratory positive airway pressure) and a
ower pressure during expiration (EPAP -- expiratory posi-
ive airway pressure). The gradient between IPAP and EPAP
pressure support ventilation) is crucial in maintaining ade-
uate alveolar ventilation and reducing paCO2.2,3 The IPAP
cts also in reducing the work of breathing and fatigue,
educing the workload of respiratory muscles; EPAP has the
unction of maintaining the patency of the upper airway,
o control obstructive apnea and to improve the functional
esidual capacity.3,65 BIPAP is now proposed for the type of
atients who require high expiratory pressures to control
bstructive sleep apnea--hypoapnea, but who cannot tol-
rate exhaling against a high-ﬁxed CPAP pressure.65 Other
ndications of BIPAP are the treatment of coexisting cen-
ral apnea or hypoventilation, the obesity-hypoventilation
yndrome, the overlap syndrome and neuromuscular dis-
rders. Although the patient should be able to maintain
pontaneous breathing, it is used to set a back-up rate
ption for those patients whose ventilation during sleep may
e particularly impaired (neuromuscular disorders, complex
leep apnea, central apnea in chronic heart failure, obesity-
ypoventilation syndrome).3,65 Recently a new device has
een introduced: an auto-adjusting bi-level positive airway
ressure (auto-BIPAP) to provide greater ﬂexibility in pres-
ure changes for bi-level therapy. This treatment results in
HI (apnea--hypoapnea index) reduction equivalent to that
rovided by a conventional BIPAP.66
verage volume-assured pressure support
entilation (AVAPS)
verage volume-assured pressure support ventilation
AVAPS) is used in patients with chronic hypoventilation and
n particular with obesity hypoventilation syndrome,67 neu-
omuscular diseases, and sometimes, in chronic obstructive
ulmonary disease. In this mode a target tidal volume is
et; the device adjusts the pressure support which to reach
he selected tidal volume. It guarantees a delivered tidal
NIV and sleep disorders 329
Table 4 Types of non invasive positive pressure ventilation.3,49,50,59
Continuous positive airway pressure (CPAP)
Applications: obstructive sleep apnea; congestive heart failure with coexisting obstructive sleep apnea;
Obesity-hypoventilation syndrome with coexisting obstructive sleep apnea
Setup requirements: CPAP level
Advantages: simple to use; relatively inexpensive
Disadvantages: minimal or no ventilation support; preset pressures may not address variability in obstructive sleep apnea or
severity with sleep stages and positional stages
AUTO-CPAP
Applications: obstructive sleep apnea; congestive heart failure with coexisting obstructive sleep apnea;
Obesity-hypoventilation syndrome with coexisting obstructive sleep apnea
Setup requirements range of allowable CPAP levels
Advantages: reduces number of titration studies; self-adjusting to adapt to variability in obstructive sleep apnea with sleep
stages and positional changes; maybe useful for patients with ongoing weight loss such as after bariatric surgery
Disadvantages: more expensive than ﬁxed CPAP; may not be effective for patients with cardiopulmonary disorders or other
conditions in which desaturation may be unrelated to obstructive events
Adaptive servo-ventilation (ASV)
Applications: congestive heart failure; central sleep apnea; complex sleep apnea syndrome
Setup requirements: maximum and minimum inspiratory pressures; end-expiratory pressure
Advantages: adapts pressure to maintain more consistency of respiration over time
Disadvantages: more expensive than other modes; may worsen ventilation in disease with chronic ventilator insufﬁciency such
as COPD or restrictive thoracic disorders
Bilevel positive airway pressure (BIPAP)
Without backup rate
Applications: obstructive sleep apnea with CPAP intolerance; obstructive sleep apnea with central sleep apnea; restrictive
thoracic disorders; severe chronic obstructive pulmonary disease; obesity hypoventilation syndrome with coexisting
obstructive sleep apnea and residual hypoventilation despite CPAP
Setup requirements: inspiratory and expiratory positive airway pressures
Advantages: promotes alveolar ventilation; unloads respiratory muscles; decreases the work of breathing; controls obstructive
hypopnea
Disadvantages: more expensive than CPAP; may generate central apnea
With backup rate
Applications: central sleep apnea; complex sleep apnea syndrome; worsening restrictive disorder
Setup requirements: inspiratory and expiratory positive airway pressure; backup rate; ratio of inspiratory time to expiratory
time
Advantages: provides mandatory respiratory support during central or pseudo-central apneas
Disadvantages: more expensive than conventional BIPAP; may generate central apnea
Average volume-assured pressure support (AVAPS)
Applications: obesity-hypoventilation syndrome; neuromuscular disease; chronic obstructive pulmonary disease
Setup requirements: target tidal volume (8ml/kg of ideal weight); inspiratory positive airway pressure limits; respiratory rate
Advantages: ensures a delivered tidal volume; compensates for diseases progression
Disadvantages: more expensive than other modes
A
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bvolume adjusted despite variability in the patient effort,
airway resistance, and lung or chest wall compliance. A
particular beneﬁt of this mode is that it may be modiﬁed
as the disease progresses (as it occurs in neuromuscular
disorders such as amyotrophic lateral sclerosis).3 Yet, this
system remains controversial. It is not known if and to what
extent hybrid ventilation modes (i.e. pressure-targeted
ventilation with assured volume support) are beneﬁcial in
the management of chronic hypercapnic failure. Further
large-scaled studies are needed.68
The various types of non-invasive positive pressure venti-
lation and their indications for the non-invasive ventilation
for the various disorders are shown in Tables 4 and 5.
(pplication and management of NIV
octurnal CPAP titration
he titration of the therapeutic value of CPAP (value of pos-
tive pressure necessary to eliminate the sleep apnea) can
e made with one of the following methods:1) Sleep study with complete laboratory staff dedicated to
monitoring and manual CPAP titration performed during
polysomnography (the pressure is gradually increased to
normalize the breathing pattern during sleep).52
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Table 5 Non-invasive ventilation indication.3,49,50,59
Chronic obstructive pulmonary disease (COPD)
NIV without backup rate
PaCO2 ≥50mmHg when the patient is awake and O2 saturation ≤88% (≥2 h of recording on nocturnal oximetry) while on
the higher of 2 L per minute of O2 and obstructive sleep apnea and CPAP treatment have been considered and ruled out by
facility-based nocturnal polysomnography.
NIV with backup rate, anytime after use without backup rate
PaCO2 ≥7mmHg greater than the original qualifying result and O2 saturation ≤88% for ≥5min (2 h of recording on
facility-based nocturnal polysomnography) while on NIV without backup rate and apnea--hypopnea index <5
Restrictive thoracic disorders: progressive neuromuscular disease or thoracic cage abnormalities
NIV with or without backup rate
PaCO2 ≥45mmHg or O2 saturation ≤88% for %minutes (≥2 h of recording on nocturnal oximetry) or (for neuromuscular
diseases only) maximal inspiratory pressure (MIP) ≤60 cm H2O or FVC ≤50% of predicted
Central sleep apnea or complex sleep apnea syndrome
NIV with or without backup rate
All the following on facility-based on nocturnal polysomnography: apnea--hypopnea index >5, central events >50% of
total, central events ≥5 per hour, excessive daytime sleepiness or disrupted sleep and signiﬁcant improvement on NIV and
FiO2
Obstructive sleep apnea
Continuous positive airway pressure (CPAP)
Apnea--hypopnea syndrome index/respiratory disturbance index ≥15 (minimum 30 events) or apnea--hypopnea
index/inspiratory disturbance index 5--14 with symptoms or cardiovascular risks (excessive daytime sleepiness, impaired
cognition, mood disorders, insomnia, hypertension, ischemic heart disease, history of stroke)
NIV without backup rate
Above criteria and CPAP ineffective on polysomnography or at home cardio-respiratory monitoring
Hypoventilation syndrome
NIV without backup rate
Awake PaCO2 ≥45mmHg and PaCO2 ≥7mmHg greater during sleep or upon awakening or O2 saturation ≤88% for ≥5min
(≥2 h of recording on facility-based nocturnal polysomnography) with an apnea--hypopnea index <5
NIV with backup rate
Awake PaCO2 up ≥7mmHg from initial qualifying PaCO2 despite using NIV without backup rate or O2 saturation ≤88% for
≥5min (≥2 h of recording on facility-based nocturnal polysomnography) while on NIV without backup and apnea--hypopnea
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2) Complete polysomnographic study (with or without the
continued presence of dedicated staff) with titration
performed with auto-CPAP (usually the value of the 90th
percentile).
3) Polysomnographic full study or complete cardiorespi-
ratory monitoring performed during nocturnal CPAP
therapy whose value has been obtained on the basis of
data extracted from the device auto-CPAP in the previ-
ous nocturnal recording (usually the value of the 90th
percentile).
4) Sleep study with complete laboratory staff dedicated to
monitoring and titration of CPAP polysomnography per-
formed in the course of using the split-night in which
the patient is evaluated for 50% of the night in spon-
taneously breathing and the other 50% in incremental
CPAP.1,69,70
Titration of PAP obtained by auto-CPAP therapy should
e derived from visual analysis of a large recording period
ree of artifacts. The optimum pressure value of CPAP is
he value which eliminates (in the course of a complete
olysomnographic investigation) each apnea, hypoapnea,
rterial desaturation, snoring, respiratory effort-related
g
c
i
arousal (RERA) in each stage of sleep and body position. The
ame applies in the course of a complete cardiorespiratory
onitoring.1,2 An acceptable level of CPAP leads to a low
umber of events residues during the titration procedures.
he ﬁnal value of pressure (PAP) is always a compromise
etween the function of patient adherence, the absolute
alue of PAP reached, and the clinical beneﬁts derived.
It is also recommended that the procedures for titration
f CPAP in points 2, 3 and 4 are made exclusively in patients
ith OSA in the absence of comorbidities such as COPD,
hronic heart failure, and neuromuscular disorders.1,69--71
anagement of non-invasive ventilation
nitiation and settings in case of nocturnal
entilation
he main objective of NIV use is the correction of blood
as values to near ‘‘normal’’ with the least possible dis-
omfort or sleep disturbance. It is good practice to proceed
n three successive steps.1 The ﬁrst step is to choose and
djust the ventilator settings while the patient is awake,
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fNIV and sleep disorders
assuring physiological adequacy and patient comfort for
at least 1 or 2 h. In the second step the clinician should
evaluate the adequacy of the settings when sleeping dur-
ing a nap and a night’s sleep. Different options, according
to the resources available in each center, are used. A full
polysomnography recording oxygen saturation (SpO2) and
trans-cutaneous pCO2 (PtcCO2) or end-tidal (PetCO2), ﬂow,
tidal volume, airway pressure, rib cage and abdomen excur-
sion and sleep-staging allows a complete assessment.1,2,52
When the resources are not available fewer parameters
may be used. The minimum required is recording SpO2 on
room air, assessing that the normalization of SpO2 accom-
panies the normalization, or at least the improvement in
PaCO2.
The second step relates to patient tolerance, comfort,
changes in sleep quality and well-being; these data should
be obtained. The third step consists of looking for reduction
in PaCO2 and augmentation of PaO2 without dyspnea during
the day in free ventilation after several nights of NIV. This
is done to conﬁrm that the settings are adequate for the
patient’s needs.1,71
The main purpose for the application of NIV is the cor-
rection of hypercapnia to physiological levels.52 Lately, a
technique called ‘‘high-intensity NIV’’ has emerged, apply-
ing inspiratory pressure levels up to 28 cm H2O and high
back-up respiratory rates in order to achieve pCO2 control in
stable hypercapnic COPD patients.72 This approach has been
physiologically proven to reduce inspiratory effort, when
compared to conventional ventilation strategies.73 Further-
more, high-intensity NIV does not negatively inﬂuence sleep
quality,74 and improves blood gases, lung function, hemat-
ocrit, and decrease COPD exacerbations rates.75 However, it
remains controversial what impact the setting of the breath-
ing frequency has on ventilation quality in COPD.76
If the results are not satisfactory, changes must be
made to the settings. One may also change the type of
mask and ventilator. At the beginning a starting level of
pressure support of 10 cm H2O is recommended. Contin-
uing the adaptation, the pressure level can progressively
be increased to achieve evidence of improvement. Pres-
sure support higher than 20 cm H2O is rarely necessary.1
A back-up frequency set close to the spontaneous fre-
quency of the patient during sleep is a reasonable step.1--3
When employing a volume-preset ventilator, the initial
suggested setting may be established by adjusting the
frequency of ventilator-delivered breaths so that it approxi-
mates the patient’s spontaneous breathing frequency during
sleep, an inspiratory time/total breathing time between
0.33 and 0.5 and a relatively high tidal volume of around
10--15ml/kg to insure sufﬁcient tidal volume in case of
leaks.1,71
Supplemental oxygen (O2) will be added to the ven-
tilator circuit, especially in those patients who require
oxygen during the daytime (COPD, cystic ﬁbrosis, bronchiec-
tasis). However, oxygen delivery varies greatly with the
tubing system used (active valve port, leak port circuit).
Furthermore, optimal mask ﬁtting must be titrated in a
clinical setting.77 In the absence of obstructive pulmonary
disease, the addition of O2 to the ventilation circuit may
be justiﬁed only to maintain an acceptable level of PaO2
during sleep and only after all the parameters have been
optimized.78
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he choice of the mask
he interface is of paramount importance for adherence
o NIV therapy. The choice of this device should be done
ith special care to meet patient’s needs. Considering the
ype of treatment planned and favoring masks which deliver
ositive pressure through both the nose and the mouth (if
he patient is a mouth breather) is of great importance.79
very effort should be made to minimize air leaks, max-
mize patient comfort and optimize patient--ventilator
nteraction.80 Technological issue to consider when choos-
ng the NIV interface include the site and type of exhalation
ort, and how the ventilator algorithm functions with dif-
erent masks. Heating and humidiﬁcation may be needed to
revent adverse effects from cool dry gas.80,81
ontinuous NIV
n patients with neuromuscular disorders (to a lesser degree
n end-stage stage lung disease), ventilatory dependency
an be total at the starting of non-invasive ventilation or
ay gradually increase following the progressive worsen-
ng of the disease. In case of continuous need for assisted
entilation, non-invasive ventilation may be started and
aintained with modiﬁcations of the mode of ventilation
e.g. changing ventilation mode between day and night
nd/or alternating various interface types: nasal, oral,
ronasal, mouth-piece) and associated, where possible, with
ssisted coughing.1,82
ollow-up
linical follow-up and daytime arterial blood gases should
e performed at least twice a year.1,2 The recordings dur-
ng sleep (possibly identical to those performed for the
daptation to non-invasive ventilation), are useful. At any
ime, when there are indications of unsatisfactory results
uch as the recurrence of clinical symptoms and/or signs
f hypoventilation on arterial blood gases, inadequate
on-invasive ventilation should be suspected, and a com-
lete objective assessment of ventilation during sleep with
olysomnography must be undertaken.
When the NIV is not proven to be optimal, a change of
entilation modality and/or parameters of the ventilator
nd/or a revision of the interface may be indicated. In case
f disease progression one should be considered increasing
he duration of ventilation during the day. The interfaces
eed to be regularly checked and modiﬁed or adapted to
hanging needs of the patient.1,69,71
anagement of complications
ir leaks during ventilation
he major potential adverse effect is the loss of effec-
iveness of the ventilation and therefore the potential
ragmentation of sleep. A variety of more or less effec-
ive measures have been suggested to tackle the problem of
eaks during NIV. These include the prevention of neck ﬂex-
on, the semi-recumbent positioning of the patient, the use
f a chin rest or a cervical collar to prevent opening of the
332
Table 6 Management of complications and side effects of
NIV.1,2
Complication and/or
side effect
Action
Air leaks Prevention of neck ﬂexion
Semi-recumbent positioning
Use of chin rest
Use of cervical collar
Switch to controlled pressure
mode
Decrease peak inspiratory
pressure and increase volume
Optimize the interfaces (using
oro-nasal mask)
Nasal dryness,
congestion
Cold pass over
Heated humidiﬁer
Aerofagia, eructation, Decrease peak inspiratory
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Rﬂatulence, abdominal
discomfort
pressure below 25 cm H2O
outh, switching to controlled pressure mode, decreasing
he peak inspiratory pressure and increasing the delivered
olume, optimizing the interface (using full face masks if
ossible). The effectiveness of each of these measures must
e conﬁrmed during sleep recording.83
asal dryness, congestion
s shown in the CPAP literature, the side effects of nasal
ryness, congestion, and rhinitis are related to a defect of
umidiﬁcation. For the patients with nasal and mouth dry-
ess, a cold pass over or a heated humidiﬁer can be used.84,85
erophagia
erophagia (swallowing air) is frequently reported but
s rarely intolerable. Minor clinical signs are eructation,
atulence and abdominal discomfort. Aerophagia usually
epends on the level of inspiratory pressure and is more
ommon when using a volume-controlled ventilation, espe-
ially with mouthpiece, in patients with neuromuscular
isorders. The incidence decreases if the peak inspiratory
ressure is maintained below 25 cm H2O pressure.1,85
The management of the most important complications
nd side effects is reported in Table 6
onclusions
ptimizing patient acceptance and adherence to non-
nvasive ventilation treatment is challenging and can be
nﬂuenced by several factors (i.e. age, outcome expecta-
ions, leakages, and measured efﬁcacy).86,87
Sleep-related disorders are life-threatening conditions.
he optimal level of treatment should be determined in a
leep laboratory. Side effects directly affecting the patient’s
dherence to treatment are known. The most common
re discomfort wearing the mask and leakages followed
y nasopharyngeal symptoms including increased congestion
nd rhinorrea; these effects are related to reduced humidity
f inspired gas.A. Nicolini et al.
Humidiﬁcation of delivered gas may improve these symp-
oms. Sleep specialists should review the results of objective
esting with the patient. Education of the patient is manda-
ory.
The choice of ventilator, its setting, the choice of inter-
ace between patient and ventilator are crucial for the
uccess of NIV. A variety of masks are now available and
anufacturers continue to improve mask design. Oronasal
ask should be considered if the patient is mouth breather
o avoid leaks through open mouth. In the past there were
entilators which had only pressure or volume controlled
odes. Today most ventilators can work in either mode and
he choice of the equipment should be considered by the
atient’s point of view. The patient’s point of view is clin-
cally relevant because better patient well-being is related
o a better treatment adherence. This is a critical issue
specially in patients chronically treated with non-invasive
entilation.
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